Galderma fends off Dr Reddy IPR claims
Galderma Laboratories has successfully avoided three inter partes review (IPR) petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.
In August 2015, Dr Reddy’s Laboratories filed three IPR petitions against Galderma challenging US number 8,603,506, a patent directed to the drug.
The India-based company had already filed an Abbreviated New Drug Application seeking approval to market a generic version of Oracea, prompting Galderma to sue Dr Reddy’s at the US District Court for the District of Delaware.
Stephen Maebius, partner at law firm Foley & Lardner, which represented Galderma, said: “This represents a second attempt to invalidate a patent through the IPR process pertaining to the Oracea product.
“Following our successful defence of the first IPR attack, we are very pleased that the board denied institution of all three petitions filed against the new Oracea patent in this second wave.”
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk